Quest Partners LLC Acquires 3,507 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Quest Partners LLC increased its holdings in Hims & Hers Health, Inc. (NYSE:HIMS) by 5,944.1% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,566 shares of the company’s stock after purchasing an additional 3,507 shares during the period. Quest Partners LLC’s holdings in Hims & Hers Health were worth $72,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of HIMS. Farallon Capital Management LLC lifted its stake in shares of Hims & Hers Health by 3,890.5% in the first quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock worth $25,928,000 after buying an additional 1,634,000 shares during the last quarter. M&G Plc bought a new stake in Hims & Hers Health during the first quarter valued at about $8,232,000. State of Michigan Retirement System grew its position in shares of Hims & Hers Health by 177.8% in the second quarter. State of Michigan Retirement System now owns 500,000 shares of the company’s stock valued at $10,095,000 after purchasing an additional 320,000 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of Hims & Hers Health by 67.5% in the second quarter. Bank of New York Mellon Corp now owns 678,602 shares of the company’s stock worth $13,701,000 after purchasing an additional 273,473 shares during the period. Finally, Panagora Asset Management Inc. lifted its position in shares of Hims & Hers Health by 246.2% during the 2nd quarter. Panagora Asset Management Inc. now owns 378,192 shares of the company’s stock worth $7,636,000 after purchasing an additional 268,949 shares during the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Hims & Hers Health

In related news, insider Soleil Boughton sold 2,335 shares of Hims & Hers Health stock in a transaction dated Tuesday, July 9th. The stock was sold at an average price of $20.28, for a total value of $47,353.80. Following the completion of the transaction, the insider now directly owns 169,144 shares of the company’s stock, valued at $3,430,240.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, insider Michael Chi sold 7,500 shares of Hims & Hers Health stock in a transaction on Thursday, June 20th. The stock was sold at an average price of $24.50, for a total value of $183,750.00. Following the completion of the sale, the insider now directly owns 185,326 shares of the company’s stock, valued at approximately $4,540,487. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Soleil Boughton sold 2,335 shares of the company’s stock in a transaction on Tuesday, July 9th. The shares were sold at an average price of $20.28, for a total value of $47,353.80. Following the transaction, the insider now directly owns 169,144 shares in the company, valued at approximately $3,430,240.32. The disclosure for this sale can be found here. Insiders sold 755,159 shares of company stock valued at $13,584,547 in the last three months. Corporate insiders own 17.71% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Citigroup downgraded Hims & Hers Health from a “buy” rating to a “neutral” rating and lifted their price target for the stock from $16.00 to $20.00 in a research report on Wednesday, May 22nd. Bank of America cut their target price on shares of Hims & Hers Health from $24.00 to $20.00 and set a “buy” rating for the company in a research note on Friday, September 13th. Canaccord Genuity Group raised their price target on shares of Hims & Hers Health from $20.00 to $24.00 and gave the stock a “buy” rating in a research report on Wednesday, May 22nd. Needham & Company LLC assumed coverage on shares of Hims & Hers Health in a research note on Thursday, August 22nd. They issued a “buy” rating and a $24.00 target price for the company. Finally, Deutsche Bank Aktiengesellschaft boosted their price target on Hims & Hers Health from $16.00 to $23.00 and gave the company a “hold” rating in a research note on Wednesday, August 7th. Eight analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $19.86.

Hims & Hers Health Stock Performance

Shares of NYSE:HIMS opened at $16.10 on Wednesday. The company’s fifty day moving average is $17.62 and its 200-day moving average is $17.05. Hims & Hers Health, Inc. has a 52 week low of $5.65 and a 52 week high of $25.74. The company has a market capitalization of $3.46 billion, a PE ratio of -1,610.00 and a beta of 1.05.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, August 5th. The company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. The firm had revenue of $315.65 million for the quarter, compared to analyst estimates of $302.43 million. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The company’s revenue for the quarter was up 51.8% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.03) earnings per share. On average, analysts forecast that Hims & Hers Health, Inc. will post 0.22 EPS for the current year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.